A Phase 3 interventional study of Peginterferon alfa-2a in Myelogenous Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 5 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-20.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Germany — 10 open to participants now, 16 under way, 3 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany.
Among the 90 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Germany, this one is the 60th largest by enrollment of the 77 interventional ones that give a count, is the only one that started in 2003, is one of 25 in phase 3, and was the 66th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →10 of the 90 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Germany are open now. Recruiting first, the newest first:
Thomas Ernst, Prof. Dr. med. · Sites in Germany
Ages 18+
Novartis Pharmaceuticals · Sites in Germany, United States, Australia and 14 more countries
Ages 1–18
Novartis Pharmaceuticals · Sites in Germany
Ages 18–100
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Sites in Germany, United States, Australia and 6 more countries
Ages 18+
Ascentage Pharma Group Inc. · Sites in Germany, United States, Australia and 13 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 39 · Phase 3 25 · Phase 4 5
First in 1995; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is close to the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 171 across the 77 interventional studies, 330 across the 12 observational. Of the 65 that completed or were terminated, 36 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 90 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 2 studies filed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive — fewer than ten, so there is no comparison to draw.
3 of the studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06423911Phase 3Ascentage Pharma Group Inc.Study of Olverembatinib (HQP1351) in Patients With CML-CP | 2027-06-30 |
| NCT03906292University of JenaFrontline Asciminib Combination in Chronic Phase CML | 2027-03 |
| NCT04925479Novartis PharmaceuticalsStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | 2027-09-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 90 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety and tolerability of long-term use of peginterferon alfa-2a in participants with CML who have previously participated in peginterferon alfa-2a study ML16544 (NCT number not available), NO16006 (NCT number not available) or ML17228 (NCT number not available) and treating physician has decided to continue treatment with peginterferon alfa-2a within the frame of another clinical study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive peginterferon alfa-2a subcutaneously in doses between 90 and 450 microgram (mcg) once weekly until medically indicated as judged by the treating investigator.
Drug: Peginterferon alfa-2a
Peginterferon alfa-2a in doses between 90 and 450 mcg will be administered subcutaneously once weekly until medically indicated as judged by the treating investigator.
Also known as: Pegasys
Number of Participants With Complete Hematologic Response
Hematologic response was considered to be achieved if participants met all of the following criteria: normalization of white blood cells count to less than (\<) 10\*10\^9 per liter (/L) with normal differentiation, normalization of platelet count at \<450\*10\^9/L, and disappearance of all signs and symptoms of the disease. This response had to be confirmed at least 4 weeks after the first measure and beyond that.
Time frame: Up to approximately 7 years
Time to Loss of Previous Hematologic Response
Time to loss of previous hematologic response was defined as the interval between the first day of treatment in the study and the first day of loss of previous hematologic response during elapsed time of study. Hematologic response was considered to be achieved if participants met all of the following criteria: normalization of white blood cells count to \<10\*10\^9/L with normal differentiation, normalization of platelet count at \<450\*10\^9/L, and disappearance of all signs and symptoms of the disease. This response had to be confirmed at least 4 weeks after the first measure and beyond that.
Time frame: Up to approximately 7 years
Number of Participants With Major Cytogenetic Response (CyR)
CyR was based on the prevalence of Philadelphia chromosome-positive (Ph+) bone marrow cells in metaphase determined from reverse transcriptase polymerase chain reaction (RT-PCR). Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was absence of detectable Ph+ bone marrow cells and PCyR was achieved when 1 to 34 percent (%) of bone marrow cells were Ph+.
Time frame: Up to approximately 7 years
Time to Loss of Previous CyR
Time to loss of previous CyR was defined as the interval between the first day of treatment in the study and the first day of loss of previous CyR. CyR is based on the prevalence of Ph+ bone marrow cells in metaphase. Major CyR was categorized as either CCyR or PCyR. CCyR was achieved when there was absence of detectable Ph+ bone marrow cells and PCyR was achieved when 1 to 34% of bone marrow cells were Ph+.
Time frame: Up to approximately 7 years
Number of Participants With Molecular Response (MR)
MR was assessed using breakpoint cluster region - Abelson (BCR-ABL) proto-oncogene transcript levels measured by RT-PCR from peripheral blood. Number of participants with BCR-ABL/ABL ratio less than or equal to 10 (%) was reported.
Time frame: Up to approximately 7 years
Time to Loss of Previous MR
Time to loss of previous MR was defined as the interval between the first day of treatment in the study and the first day of loss of previous MR. MR was assessed using BCR-ABL transcript levels measured by RT-PCR from peripheral blood.
Time frame: Up to approximately 7 years
| Milestone | Peginterferon Alfa-2a |
|---|---|
| Started | 41 |
| Completed | 25 |
| Not completed | 16 |
| Withdrew: Adverse event | 8 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Other | 5 |
Hematologic response was considered to be achieved if participants met all of the following criteria: normalization of white blood cells count to less than (\<) 10\*10\^9 per liter (/L) with normal differentiation, normalization of platelet count at \<450\*10\^9/L, and disappearance of all signs and symptoms of the disease. This response had to be confirmed at least 4 weeks after the first measure and beyond that.
| participants | Peginterferon Alfa-2a |
|---|---|
| Number of Participants With Complete Hematologic Response | 40 |
Time to loss of previous hematologic response was defined as the interval between the first day of treatment in the study and the first day of loss of previous hematologic response during elapsed time of study. Hematologic response was considered to be achieved if participants met all of the following criteria: normalization of white blood cells count to \<10\*10\^9/L with normal differentiation, normalization of platelet count at \<450\*10\^9/L, and disappearance of all signs and symptoms of the disease. This response had to be confirmed at least 4 weeks after the first measure and beyond that.
| months | Peginterferon Alfa-2a |
|---|---|
| Time to Loss of Previous Hematologic Response | NA (NA to NA) |
CyR was based on the prevalence of Philadelphia chromosome-positive (Ph+) bone marrow cells in metaphase determined from reverse transcriptase polymerase chain reaction (RT-PCR). Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was absence of detectable Ph+ bone marrow cells and PCyR was achieved when 1 to 34 percent (%) of bone marrow cells were Ph+.
| participants | Peginterferon Alfa-2a |
|---|---|
| Number of Participants With Major Cytogenetic Response (CyR) | 40 |
Time to loss of previous CyR was defined as the interval between the first day of treatment in the study and the first day of loss of previous CyR. CyR is based on the prevalence of Ph+ bone marrow cells in metaphase. Major CyR was categorized as either CCyR or PCyR. CCyR was achieved when there was absence of detectable Ph+ bone marrow cells and PCyR was achieved when 1 to 34% of bone marrow cells were Ph+.
| years | Peginterferon Alfa-2a |
|---|---|
| Time to Loss of Previous CyR | NA (NA to NA) |
MR was assessed using breakpoint cluster region - Abelson (BCR-ABL) proto-oncogene transcript levels measured by RT-PCR from peripheral blood. Number of participants with BCR-ABL/ABL ratio less than or equal to 10 (%) was reported.
| participants | Peginterferon Alfa-2a |
|---|---|
| Number of Participants With Molecular Response (MR) | 38 |
Time to loss of previous MR was defined as the interval between the first day of treatment in the study and the first day of loss of previous MR. MR was assessed using BCR-ABL transcript levels measured by RT-PCR from peripheral blood.
| years | Peginterferon Alfa-2a |
|---|---|
| Time to Loss of Previous MR | NA (NA to NA) |
Collected over Up to approximately 7 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Peginterferon Alfa-2a | — | 13/41 (31.7%) | 35/41 (85.4%) |
| Event | Peginterferon Alfa-2a |
|---|---|
| General physical health deteriorationGeneral disorders | 2/41 |
| CholelithiasisHepatobiliary disorders | 2/41 |
| Atrial fibrillationCardiac disorders | 1/41 |
| Intestinal haemorrhageGastrointestinal disorders | 1/41 |
| CholecystitisHepatobiliary disorders | 1/41 |
| AppendicitisInfections and infestations | 1/41 |
| CellulitisInfections and infestations | 1/41 |
| GastroenteritisInfections and infestations | 1/41 |
| InfectionInfections and infestations | 1/41 |
| PneumoniaInfections and infestations | 1/41 |
| Event | Peginterferon Alfa-2a |
|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/41 |
| DepressionPsychiatric disorders | 7/41 |
| FatigueGeneral disorders | 5/41 |
| Influenza like illnessGeneral disorders | 5/41 |
| BronchitisInfections and infestations | 5/41 |
| NasopharyngitisInfections and infestations | 5/41 |
| Back painMusculoskeletal and connective tissue disorders | 5/41 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 5/41 |
| ErythemaSkin and subcutaneous tissue disorders | 5/41 |
| NeutropeniaBlood and lymphatic system disorders | 4/41 |
Analysis population included all enrolled participants.
| Age, Continuous(years) | Peginterferon Alfa-2a |
|---|---|
| Mean | 48.5 ± 14.1 |
| Sex: Female, Male(Participants) | Peginterferon Alfa-2a |
|---|---|
| Female | 14 |
| Male | 27 |
The record gives a start of Sep 2003, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 5 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →